`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`_____________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`_____________________
`
`
`ARGENTUM PHARMACEUTICALS LLC,
`Petitioner,
`
`v.
`
`CIPLA LTD.
`Patent Owner.
`_____________________
`
`Case IPR2017-00807
`Patent 8,168,620 B2
`_____________________
`
`CIPLA LTD.’S
`CORRECTED REQUEST FOR ORAL ARGUMENT
`
`
`
`
`
`
`
`Mail Stop "PATENT BOARD"
`Patent Trial and Appeal Board
`U.S. Patent and Trademark Office
`P.O. Box 1450
`Alexandria, VA 22313-1450
`
`
`
`
`
`Cipla Ltd.’s Request for Oral Argument
`IPR2017-00807
`
`Pursuant to the Board’s August 21, 2017 Scheduling Order (Paper 12), Patent
`
`Owner Cipla Ltd. respectfully requests oral argument, currently scheduled for May
`
`16, 2018, on the issues raised in the Petition for Inter Partes Review of U.S. Patent
`
`No. 8,168,620; Patent Owner’s Response; and Petitioner’s Reply to Patent Owner
`
`Response. The issues to be argued:
`
`1.
`
`The construction of the terms “suitable for nasal administration” and
`
`“nasal spray” as found in independent claims 1, 24 and 25;
`
`2. Whether claims 1, 4-6, 24-26, and 29 are unpatentable as obvious in
`
`view of Hettche, Phillipps, and Segal;
`
`3. Whether claims 42-44 are unpatentable as obvious in view of Hettche,
`
`Phillipps, Segal, and Flonase label;
`
`4.
`
`5.
`
`6.
`
`Any issues raised by Petitioner in its request for oral hearing;
`
`Rebuttal to Petitioner’s presentation on all matters;
`
`Any other issues raised in papers filed in this proceeding, including
`
`issues raised in papers yet to be filed, such as Motions to Exclude and Motions for
`
`Observations on Cross-examination of Reply Witness; and
`
`7.
`
`Any other outstanding motions or pleading, or any other issues the
`
`Board deems necessary for issuing a final written decision.
`
`-1-
`
`
`
`Patent Owner requests one (1) hour in which to present its arguments.
`
`Cipla Ltd.’s Request for Oral Argument
`IPR2017-00807
`
`
`Patent Owner requests that the Board provide audio-visual equipment to
`
`display demonstrative exhibits, including a projector and screen for displaying
`
`documents from a computer.
`
`
`
`
`
`
`
`
`
`
`
`Respectfully submitted,
`STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.
`
`
`
`
`Dennies Varughese (Reg. No. 61,868)
`Lead Attorney for Patent Owner
`
`
`Date: April 9, 2018
`1100 New York Avenue, N.W.
`Washington, D.C. 20005-3934
`(202) 371-2600
`
`
`
`- 2 -
`
`
`
`
`
`
`
`CERTIFICATE OF SERVICE (37 C.F.R. §§ 42.6(e))
`
`The undersigned hereby certifies that the above-captioned “Cipla Ltd.’s
`
`Request for Oral Argument” was served in its entirety on April 9, 2018, upon the
`
`following parties via email:
`
`Michael R. Houston: mhouston@foley.com
`Joseph P. Meara: jmeara@foley.com
`James P. McParland: jmcparland@foley.com
`Andrew R. Cheslock: acheslock@foley.com
`Tyler C. Liu: TLiu@agpharm.com
`ARG-dymista@foley.com
`
`
`Respectfully submitted,
`STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.
`
`
`
`
`Dennies Varughese (Reg. No. 61,868)
`Lead Attorney for Patent Owner
`
`
`
`
`
`
`
`
`
`
`
`
`Date: April 9, 2018
`1100 New York Avenue, N.W.
`Washington, D.C. 20005-3934
`(202) 371-2600
`9202024.1
`
`
`
`
`